STI-6129 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 2 |
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05692908 (ClinicalTrials.gov) | March 2023 | 11/1/2023 | An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis | An Open-Label, Dose-Escalation Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis | Light Chain (AL) Amyloidosis | Biological: STI-6129 | Sorrento Therapeutics, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 36 | Phase 1 | NULL |
| 2 | NCT04316442 (ClinicalTrials.gov) | April 1, 2021 | 16/3/2020 | Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis | A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL Amyloidosis | Light Chain (AL) Amyloidosis | Biological: STI-6129 | Sorrento Therapeutics, Inc. | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 1/Phase 2 | United States |